Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 141.30 4.40
Tata Mot 428.65 4.24
Bhel 181.05 3.10
Tata Stl 418.80 1.22
Ntpc Ltd 123.05 0.37
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-GUFIC Biosciences Limited
GUFIC Biosciences Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:509079NSE:GUFICBIOBloomberg:CF@INReuters:GUFI.BO
Market Lot: 1Face Value: 1ISIN Demat: INE742B01025
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
17-JAN-11 Credit rating agency, CRISIL Equities has assigned a CRISIL IER fundamental grade of 2/5 to C&C Constructions (C&C). 14-SEP-10 C & C Constructions has entered into a formal joint venture agreement with Isolux Corsan of Spain on September 09, 2010. 05-MAY-10 Anagram has recommended `Buy` on C & C Construction with a price target of Rs 341 as against the market price (CMP) of Rs 238 in its report dated May. 5, 2010. 18-MAR-10 Anag...   More..
Business Profile Future Plans
CEO Talk
GUFIC Biosciences expects its turnover to increase by 57 per cent to Rs 63 crore in FY03. The company plans to intensify its R&D activity and raise Rs 20 crore through private placement.   Jayesh Choksi
One To One
Recent news
Latest News
GUFIC Biosciences earnings fall 21.78% for Mar`11 qtr  -IRIS 13-May-11
Previous

 


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 856.92999.83835.65
Other Income1.492.161.22
Total Income858.411001.99836.87
Cost of goods sold769.26892.58767.43
OPBDIT89.15109.4169.44
PAT30.0933.2915.27
Gross Block---
Equity capital77.3577.3577.35
EPS (Rs.)-0.430.20
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-11.86 - 22.0521.25 - 43.50
Debt / Equity (x)---
Operating margin (% of OI)10.410.9 8.3
Net margin (% of OI) 3.5 3.3 1.8
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Gufic House
Subhash Road - A
Vile Parle (East)
Mumbai
Maharashtra-400 057
PHONE
(022) 6691 9187/ 89 - 93/ 6726 1007
FAX
(022) 2611 8103/ 2616 9008
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer